Myriad Genetics Expands Minimal Residual Disease Testing for Three Cancer Types
The whole-genome sequencing assay is now available for breast, colorectal, and renal cancers following new clinical study results.
Category: Molecular Diagnostics
Molecular Diagnostics
Latest
Molecular Diagnostics
Latest
FDA Clears Rapid PCR System for Rapid Respiratory Virus Testing
The system simultaneously detects RSV, influenza A and B, and SARS-CoV-2 from a nasal swab in under 10 minutes.
Molecular Diagnostics
Latest
Study Shows Blood Test Predicts Breast Cancer Recurrence Years Before Clinical Symptoms
Monitoring circulating tumor DNA dynamics outperformed standard markers for predicting survival and relapse in early-stage patients.
Large Study Shows Multi-Cancer Early Detection Test Increases Cancer Detection
Results from the PATHFINDER 2 trial show the Galleri test identifies 6.5 times more cancers when used with standard screenings.
Read More
New Bardet-Biedl Syndrome Diagnostic Algorithm Published
Updated criteria integrate clinical manifestations and genetic testing to reduce the time required to reach an informed diagnosis.
Read More
Thermo Fisher Scientific Launches New DNA and RNA Analysis System
The integrated electrophoresis solution is designed to simplify routine verification by eliminating gel casting and buffer preparation.
Read More
Labcorp Collaborates on Trial to Expand Colorectal Cancer Genetic Testing
The multicenter study will evaluate proactive outreach to at-risk relatives and the impact of multigene panel testing on patient care.
Read More
Volta Labs Launches Automated Library Prep for Oxford Nanopore Sequencing Kits
The Callisto Sample Prep System application is optimized for the PromethION platform to support whole genome sequencing workflows.
Read More
US Settles Genetic Testing Fraud Case Against Laboratory Owner
The settlement follows a criminal conviction and addresses more than $174 million in fraudulent Medicare claims involving multiple laboratories.
Read More
ClearNote Health Raises $52 Million for Early Cancer Detection Tests
The funding will support commercial expansion of the company’s blood-based diagnostic tests and the appointment of a new president and chief operating officer.
Read More
ctDNA Blood Test May Help Guide Treatment Selection for Spreading Cancer
Research presented at ESTRO 2026 suggests circulating tumor DNA can identify which patients will benefit from combined radiation and drug therapy.
Read More
Andes Virus Shifts Hantavirus Conversation for US Labs
Emerging Andes virus cases—capable of person-to-person transmission—are prompting US clinical labs to reassess hantavirus protocols and consider travel and epidemiologic exposures beyond rodent contact.
Read More
Co-Diagnostics Develops Strategy for Ebola Bundibugyo Virus Assay
Co-Diagnostics has completed its assay development strategy for Bundibugyo virus, following the WHO’s emergency declaration and CDC’s updated traveler screening measures amid ongoing Ebola outbreaks in the DRC and Uganda.
Read More
FDA Approves Companion Diagnostic to Identify NSCLC Patients Eligible for Tepmetko
The tissue-based test identifies patients with MET exon 14 skipping alterations eligible for treatment with tepotinib.
Read More
FDA Approves Guardant Health’s New Blood-Based Cancer Test for Advanced Tumors
The FDA has approved Guardant360 Liquid CDx, a blood-based test that integrates genomic and epigenomic profiling for advanced cancer, offering a broader genomic footprint and faster results.
Read More
TGen Launches 72-Hour Whole Genome Sequencing Test for Multiple Myeloma
TGen has launched JAYseq, a clinical whole genome sequencing test for multiple myeloma that delivers results in 72 hours, enabling rapid identification of genetic changes and immunotherapy targets, according to the institute.
Read More
Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer, Study Shows
Researchers at Vanderbilt-Ingram Cancer Center report that RNA sequencing of blood samples can predict immunotherapy response in high-risk breast cancer patients.
Read More
FDA Clears Customizable Gastrointestinal Pathogen Assay
Diasorin has received FDA 510(k) clearance for its customizable LIAISON PLEX Gastrointestinal Flex Assay, allowing labs to select from 24 targets to tailor testing based on patient needs and operational priorities.
Read More
- 1
- ...
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- ...
- 106